

Chemicals/Finland, November 5, 2021 Company update

Profitability is already improving

Exel's Q3 EBIT fell way more than estimated, but guidance implies improvement is already happening and we expect Exel to be back on its earlier EBIT track soon enough.

Q3 EBIT was weak but Q4 will already be a lot better


O3 revenue grew 28% y/y to EUR 33.4m vs the EUR 30.4m/30.6m Evli/cons. estimates. Buildings and infrastructure, the most significant contributor, grew 64% but positive top line development was broad; Exel also sees stabilization in Transportation, where the pandemic hit demand. Inflation had only a limited impact as Exel was able to transfer the effect of higher raw material prices forward, and Exel's pricing continues to advance. Profitable growth thus continued excluding the US unit, where a high-volume Wind power product's ramp-up costs ate all other EBIT. Exel's Q3 adj. EBIT was EUR 0.1m vs the EUR 1.9m/1.7m Evli/cons. estimates. The US labor market challenges exacerbated the production problem. The US unit's performance is expected to improve already in Q4, but in our view it will not perform according to requirements at least before Q2'22.

We make relatively small revisions to our FY '22 estimates

Exel announced its long-planned Indian expansion. We view the Indian JV a practical step to serve existing global customers in a new growth geography and a chance to sign new accounts. We reckon the Indian plant (which we expect to be driven by Wind power but not entirely) has an output smaller than that of Exel's existing assets. We expect the JV to add ca. EUR 5m in annual revenue starting next year, considering Exel owns 55% of the entity, and we believe valuation is below 1x EV/S. Exel's FY '21 adj. EBIT margin is to remain a modest 5%, but profitability should already improve by 400bps q/q in Q4. We raise our FY '22 revenue estimate to EUR 147m (prev. EUR 139m) due to the continued strong outlook as well as the Indian contribution.

In our view annual EBIT is to rebound above EUR 10m soon FY '21 EBIT isn't meaningful since Exel has managed above EUR

2.5m quarterly EBIT many times with a significantly lower top line than what will be seen next year. In our view Exel is unlikely to reach the 10% target margin in FY '22 as the US unit probably doesn't fully perform in the early part of the year. We don't view Exel's 7x EV/EBITDA and 10x EV/EBIT multiples (on our FY '22 estimates) challenging. We retain our EUR 10 TP and BUY rating.



Share price, EUR (Last trading day's closing price)	7.52
Target price, EUR	10.0
Latest change in recommendation	20-Jul-21
Latest report on company	17-Sep-21
Research paid by issuer:	YES
No. of shares outstanding, '000's	11,897
No. of shares fully diluted, '000's	11,897
Market cap, EURm	89
Free float, %	100.0
Exchange rate EUR/USD	1.17
Reuters code	EXL1V.HE
Bloomberg code	EXL1V FH
Average daily volume, EURm	0.1
Next interim report	15-Feb-22
Web site	www.exelcomposites.com
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com

■ BUY ☐ HOLD ■ SELL

+358 44 430 9071

KEY FIGU	RES										
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield	DPS EUR	
2019	103.8	5.1	4.9%	0.7	0.20	32.5	1.0	21.0	0.9	0.18	
2020	108.6	9.4	8.7%	0.5	0.45	16.4	1.1	12.5	0.6	0.20	
2021E	129.9	4.4	3.4%	-1.5	0.16	46.9	1.0	28.1	-1.7	0.25	
2022E	146.8	12.0	8.2%	4.9	0.64	11.7	8.0	10.1	5.4	0.30	
2023E	157.0	15.2	9.7%	9.2	0.92	8.2	0.7	7.6	10.3	0.32	
Market cap	o, EURm		89 G	earing 2021E,	0/0		3, %	26.8			
Net debt 2	021E, EURm		34 P	rice/book 2021	ΙE		3.2 CAGR sales 2020-23, %				
Enterprise	value, EURm		123 D	ividend yield 2	2021E, %		3.3 ROE 2	021E, %		6.7	
Total asset	s 2021E, EURn	n	107 Ta	ax rate 2021E,	0/0		56.6 ROCE	2021E, %		6.2	
Goodwill 2	021E, EURm		13 E	quity ratio 202	21E, %		26.3 PEG, P	P/E 21/CAGR		0.5	

Telephone



Chemicals/Finland, November 5, 2021 Company update

Estimates and peer group multiples

Exel Composites	2019	Q1'20	Q2'20	Q3'20	Q4'20	2020	Q1'21	Q2'21	Q3'21	Q4'21e	2021e
Buildings and infrastructure	23.5	6.2	5.3	4.9	7.0	23.5	7.0	8.7	8.1	8.5	32.3
Equipment and other industries	18.6	6.1	4.0	4.3	5.1	19.5	5.6	5.2	5.4	5.4	21.7
Wind power	23.6	5.8	7.9	7.8	6.6	28.1	7.4	7.8	8.6	7.9	31.7
Machinery and electrical	14.4	3.8	4.8	3.3	3.7	15.5	3.7	5.1	4.8	4.2	17.7
Transportation	13.1	3.4	2.8	2.2	1.9	10.2	2.5	2.7	2.1	2.1	9.4
Defense	2.3	1.3	8.0	1.9	1.4	5.3	2.2	1.8	2.2	1.8	8.0
Telecommunications	8.2	1.2	1.7	1.7	1.8	6.5	2.5	2.3	2.3	2.1	9.2
Revenue	103.8	27.8	27.2	26.0	27.5	108.6	31.0	33.5	33.4	32.0	129.9
y/y change, %	7 %	3 %	3 %	10 %	3 %	5 %	11 %	23 %	28 %	16 %	20 %
Adjusted EBIT	7.2	2.1	2.9	2.0	2.7	9.7	2.5	2.5	0.1	1.3	6.3
EBIT	5.1	1.9	2.8	2.0	2.7	9.4	2.4	2.4	-1.7		4.4
-margin, %	6.9 %	7.5 %	10.6 %	7.8 %	9.9 %	8.9 %	7.9 %	7.3 %	0.3 %	4.1 %	4.9 %
-margin (reported), %	4.9 %	6.7 %	10.2 %	7.8 %	9.9 %	8.7 %	7.8 %	7.0 %	-5.1 %		3.4 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	20	21	22	20	21	22	20	21	22
Gurit Holding	733		17.7x	13.9x		24.4x	17.6x	11.1 %	7.0 %	9.1 %
Hexagon Composites	749	58.0x	97.9x	139.1x				-1.9 %	-5.6 %	-6.6 %
Hexcel	4216	26.6x	28.2x	17.9x	351.9x	110.9x	32.5x	0.9 %	3.8 %	10.8 %
Avient	4555	13.0x	11.8x	10.7x	18.9x	16.6x	14.1x	8.1 %	8.5 %	9.5 %
SGL Carbon	1027	7.2x	10.2x	8.5x		22.5x	15.9x	-10.9 %	5.7 %	7.7 %
TPI Composites	1057	22.7x	20.0x	12.3x	85.8x		27.8x	1.5 %	0.0 %	3.0 %
Peer Group Average	2056	25.5x	31.0x	33.7x	152.2x	43.6x	21.6x	1.5 %	3.2 %	5.6 %
Peer Group Median	1042	22.7x	18.9x	13.1x	85.8x	23.5x	17.6x	1.2 %	4.8 %	8.4 %
Exel Composites (Evli est.)	89	7.7x	11.5x	6.8x	12.5x	28.1x	10.1x	8.7 %	3.4 %	8.2 %
Exel Composites prem./disc. to peer media	an	-66 %	-39 %	-48 %	-85 %	20 %	-43 %	613 %	-29 %	-2 %

Source FactSet, Evli Research

Chemicals/Finland, November 5, 2021 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	7.52 PV of Free Cash Flow	81 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	13.77 PV of Horizon value	115 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	83.1 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	15.1 Marketable securities	12 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	12.6 Debt - dividend	-44 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	58.7 Value of stock	164 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2020	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	Horizon
Net sales	109	130	147	157	165	170	174	178	181	185	187	190
Sales growth, %	4.6	19.6	13.0	7.0	5.0	3.0	2.5	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	9	4	12	15	17	18	18	19	20	21	22	22
Operating income margin, %	8.7	3.4	8.2	9.7	10.2	10.5	10.5	10.5	11.0	11.5	11.5	11.5
+ Depreciation+amort.	6	6	6	6	6	6	6	5	5	6	6	
EBITDA	15	11	18	21	23	24	24	24	25	27	27	
- Paid taxes	-3	-2	-3	-3	-4	-4	-4	-4	-4	-4	-5	
- Change in NWC	3	-3	-2	-1	-1	-1	-1	0	0	0	0	
NWC / Sales, %	11.2	11.3	11.4	11.5	11.5	11.5	11.6	11.6	11.6	11.6	11.6	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-13	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5	
opCAPEX / Sales, %	11.9	5.5	4.5	4.1	3.9	3.8	3.7	3.3	3.3	3.3	3.2	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	2	0	7	12	13	15	15	15	15	16	17	244
= Discounted FCFF		0	7	10	10	10	10	9	9	8	8	115
= DFCF min WACC		0	7	10	10	11	10	9	9	9	8	129
= DFCF max WACC		0	7	10	10	10	10	9	8	8	8	103

Chemicals/Finland, November 5, 2021 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2020Q1	2020Q2	2020Q3	2020Q4	2020	2021Q1	2021Q2	2021Q3	2021Q4E	2021E	2022E	2023E
· · · · · · · · · · · · · · · · · · ·												
Net sales	27.8	27.2	26.1	27.5	108.6	31.0	33.5	33.4	32.0	129.9	146.8	157.0
EBITDA	3.4	4.3	3.5	4.1	15.3	4.0	3.9	0.0	2.8	10.7	18.0	21.2
EBITDA margin (%)	12.1	15.8	13.5	14.8	14.1	13.0	11.7	-0.1	8.8	8.2	12.3	13.5
EBIT	1.9	2.8	2.0	2.7	9.4	2.4	2.4	-1.7	1.3	4.4	12.0	15.2
EBIT margin (%)	6.7	10.3	7.8	9.9	8.7	7.8	7.0	-5.1	4.1	3.4	8.2	9.7
Net financial items	-0.6	0.2	-0.7	-1.2	-2.3	0.5	-0.5	0.4	-0.4	0.0	-1.6	-1.4
Pre-tax profit	1.3	2.9	1.3	1.5	7.1	2.9	1.9	-1.3	0.9	4.4	10.4	13.8
Tax	-0.6	-0.4	-0.2	-0.4	-1.7	-0.9	-0.5	-0.9	-0.2	-2.5	-2.8	-2.9
Tax rate (%)	49.4	15.3	15.1	29.4	24.6	30.8	25.4	-68.9	21.0	56.6	26.8	21.0
Net profit	0.7	2.5	1.1	1.1	5.4	2.0	1.4	-2.2	0.7	1.9	7.6	10.9
EPS	0.06	0.21	0.09	0.09	0.45	0.17	0.12	-0.19	0.06	0.16	0.64	0.92
EPS adjusted (diluted no. of shares)	0.06	0.21	0.09	0.09	0.45	0.17	0.12	-0.19	0.06	0.16	0.64	0.92
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.25	0.30	0.32
SALES, EURm												
Exel Composites	27.8	27.2	26.1	27.5	108.6	31.0	33.5	33.4	32.0	129.9	146.8	157.0
Total	27.8	27.2	26.1	27.5	108.6	31.0	33.5	33.4	32.0	129.9	146.8	157.0
SALES GROWTH, Y/Y %												
Exel Composites	2.6	2.6	10.5	3.4	4.6	11.3	23.3	28.0	16.3	19.6	13.0	7.0
<u>Total</u>	2.6	2.6	10.5	3.4	4.6	11.3	23.3	28.0	16.3	19.6	13.0	7.0
EBIT, EURm												
Exel Composites	1.9	2.8	2.0	2.7	9.4	2.4	2.4	-1.7	1.3	4.4	12.0	15.2
Total	1.9	2.8	2.0	2.7	9.4	2.4	2.4	-1.7	1.3	4.4	12.0	15.2
EBIT margin, %												
Exel Composites	6.7	10.3	7.8	9.9	8.7	7.8	7.0	-5.1	4.1	3.4	8.2	9.7
Total	6.7	10.3	7.8	9.9	8.7	7.8	7.0	-5.1	4.1	3.4	8.2	9.7

Chemicals/Finland, November 5, 2021 Company update

Sales 73.1 86.3 96.6 10.08 10.06 129.9 14.68 Sales growth field 8-87 11.7 7.5 4.6 193.6 13.0 BBITDA 3.8 9.3 7.7 10.7 15.3 10.7 18.0 BBITDA 3.2 3.2 3.2 -5.5 -6.6 -5.6 -6.8 -6.0 -6.0 BBITDA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0<	2018 2019 2020 2021E 2022E 2023E	2018	2017	2016	INCOME STATEMENT, EURm
BBITDA	96.6 103.8 108.6 129.9 146.8 157.0	96.6	86.3	73.1	Sales
EMITIA margin (hb) 5.2 10.8 8.0 10.3 14.1 8.2 12.3 Deprication 3.2 3.2 3.5 5.5 5.6 3.8 -6.3 -8.0 EBIT 0.6 6.1 2.2 5.1 9.4 4.4 12.0 CBIT margin (hb) 0.6 6.1 2.2 5.1 9.4 4.4 12.0 EBIT margin (hb) 0.6 6.1 2.2 5.1 9.4 4.4 12.0 EBIT margin (hported) 1.6 7.7 2.3 4.9 8.7 3.4 8.2 EBIT margin (hported) 1.6 7.7 -0.5 -1.2 -3.3 0.0 -1.6 EBIT margin (hported) 1.6 7.7 -0.5 -1.2 -2.3 3.4 8.2 EBIT margin (hported) 1.6 7.1 -2.3 4.9 8.7 3.4 8.2 EBIT margin (hported) 1.6 7.1 -0.3 1.7 1.0 0.0 0.0	<i>11.9 7.5 4.6 19.6 13.0 7.0</i>	11.9	18.1	-8.9	Sales growth (%)
Depreciation	7.7 10.7 15.3 10.7 18.0 21.2	7.7	9.3	3.8	EBITDA
BBITA	8.0 10.3 14.1 8.2 12.3 13.5	8.0	10.8	5.2	EBITDA margin (%)
Boadwill amortization writedown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	-5.5 -5.6 -5.8 -6.3 -6.0 -6.0	-5.5	-3.2	-3.2	Depreciation
BIT	2.2 5.1 9.4 4.4 12.0 15.2	2.2	6.1	0.6	EBITA
EBIT margin fleyl 0.8 7.7 2.3 4.9 8.7 3.4 8.2 Reported BIT -1.2 6.1 2.2 5.1 9.4 4.4 12.0 BET Imargin feported fleyl -1.6 2.7 2.3 4.9 8.7 3.4 8.2 Net financials -0.1 -0.7 -0.5 -1.2 -2.3 0.0 -1.6 Ter-tax profit 0.5 5.4 1.7 3.9 7.1 4.4 10.4 Taxes 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0	0.0	0.0	0.0	Goodwill amortization / writedown
Reported BIT	2.2 5.1 9.4 4.4 12.0 15.2	2.2	6.1	0.6	EBIT
EBIT magin freported) (Wh) -1.6 7.7 -2.3 4.9 8.7 3.4 8.2 Net financials -0.1 -0.7 -0.5 -1.2 -2.3 0.0 -1.6 Tre-tax profit 0.5 5.4 1.7 3.9 7.1 4.4 10.4 Taxes -0.2 -1.2 -1.3 -1.5 -1.7 -2.5 -2.8 Minority shares 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Sest St -1.8 0.0 0.0 0.0 0.0 0.0 0.0 BASES Fixed assets 17 16 21 23 3.0 3.0 3.13 Sects St 17 16 21 23 3.0 3.0 3.13 Sect St St 17 16 21 23 3.0 3.1 3.1 Right of use assets 17 16 21 23 4 4 4	2.3 4.9 8.7 3.4 8.2 9.7	2.3	7.1	0.8	EBIT margin (%)
Net financials	2.2 5.1 9.4 4.4 12.0 15.2	2.2	6.1	-1.2	Reported EBIT
Pre-tax profit 0.5 5.4 1.7 3.9 7.1 4.4 10.4 Taxes -0.2 -1.2 -1.3 -1.5 -1.7 -2.5 -2.8 Minority shares 0.0 0.0 0.0 0.0 0.0 0.0 Net profit -1.4 4.2 0.4 2.4 5.4 1.9 7.6 Cash NRIs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	2.3 4.9 8.7 3.4 8.2 9.7	2.3	7.1	-1.6	EBIT margin (reported) (%)
Taxes -0.2 -1.2 -1.3 -1.5 -1.7 -2.5 -2.8 Minority shares 0.0 0.0 0.0 0.0 0.0 0.0 Cssh NRIs -1.8 0.0 0.0 0.0 0.0 0.0 Cssh NRIs -1.8 0.0 0.0 0.0 0.0 0.0 Nation of the properties of the	-0.5 -1.2 -2.3 0.0 -1.6 -1.4	-0.5	-0.7	-0.1	Net financials
Minority shares	1.7 3.9 7.1 4.4 10.4 13.8	1.7	5.4	0.5	Pre-tax profit
Net profit	-1.3 -1.5 -1.7 -2.5 -2.8 -2.9	-1.3	-1.2	-0.2	Taxes
Cash NRIs -1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0	0.0	0.0	0.0	Minority shares
Non-cash NRIs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.4 2.4 5.4 1.9 7.6 10.9	0.4	4.2	-1.4	Net profit
Assets	0.0 0.0 0.0 0.0 0.0 0.0	0.0	0.0	-1.8	Cash NRIs
Assets Fixed assets 17 16 21 23 30 30 31 Right of use assets 10 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 14 4 4 14 14 16 15 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20	0.0 0.0 0.0 0.0 0.0 0.0	0.0	0.0	0.0	Non-cash NRIs
Assets Fixed assets 17 16 21 23 30 30 31 Right of use assets 10 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 14 4 4 14 14 16 15 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20					BALANCE SHEET, EURm
Goodwill 10 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 4 4 4 4 4 4 4 4 4 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 </td <td></td> <td></td> <td></td> <td></td> <td></td>					
Right of use assets 0 0 5 5 3 4 4 Inventory 9 12 15 17 16 19 22 Receivables 10 15 20 20 21 25 28 Liquid funds 7 8 5 7 12 14 16 Total assets 54 64 79 85 97 107 116 Liabilities 8 64 79 85 97 107 116 Shareholder's equity 27 29 26 26 29 28 33 Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td< td=""><td>21 23 30 30 31 31</td><td>21</td><td>16</td><td>17</td><td>Fixed assets</td></td<>	21 23 30 30 31 31	21	16	17	Fixed assets
Inventory	13 13 13 13 13 13	13	13	10	Goodwill
Receivables 10 15 20 20 21 25 28 Liquid funds 7 8 5 7 12 14 16 Total assets 54 64 79 85 97 107 116 Liabilities 8 29 26 26 29 28 33 Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0<	5 5 3 4 4 5	5	0	0	Right of use assets
Receivables 10 15 20 20 21 25 28 Liquid funds 7 8 5 7 12 14 16 Total assets 54 64 79 85 97 107 116 Liabilities 8 5 7 12 14 16 Shareholder's equity 27 29 26 26 29 28 33 Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <t< td=""><td>15 17 16 19 22 23</td><td>15</td><td>12</td><td>9</td><td>Inventory</td></t<>	15 17 16 19 22 23	15	12	9	Inventory
Liquid funds 7 8 5 7 12 14 16 Total assets 54 64 79 85 97 107 116 Liabilities 7 29 26 26 29 28 33 Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		20	15	10	•
Total assets Liabilities 54 64 79 85 97 107 116 Shareholder's equity 27 29 26 29 28 33 Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					
Liabilities Shareholder's equity 27 29 26 26 29 28 33 Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	79 85 97 107 116 121	79	64	54	•
Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					Liabilities
Minority interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	26 26 29 28 33 40	26	29	27	Shareholder's equity
Convertibles 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <t< td=""><td>0 0 0 0 0 0</td><td>0</td><td>0</td><td>0</td><td></td></t<>	0 0 0 0 0 0	0	0	0	
Deferred taxes 1 0 0 0 0 0 0 Interest bearing debt 14 16 30 32 40 44 44 Non-interest bearing current liabilities 12 18 18 21 24 29 32 Other interest-free debt 1 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 0 -2 -2 -3 -3 -1 1 1 3 -3 -2 -2 -2 -2 -2 -2 -2 -2 -1 -1 -1 1 <		0	0	0	•
Deferred taxes 1 0 0 0 0 0 0 Interest bearing debt 14 16 30 32 40 44 44 Non-interest bearing current liabilities 12 18 18 21 24 29 32 Other interest-free debt 1 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3 4 2 4 4 5	3	0	0	Lease liabilities
Interest bearing debt 14 16 30 32 40 44 44 Non-interest bearing current liabilities 12 18 18 21 24 29 32 Other interest-free debt 1 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 -2 -2 -2 -2 -2 -2 -2 -3 -3 -2 -1 -1 1 0 0 0 0 0 0 0 0 0 0 0		0	0	1	Deferred taxes
Non-interest bearing current liabilities 12 18 18 21 24 29 32 Other interest-free debt 1 0 2 2 2 2 2 2 Total liabilities 54 64 79 85 97 107 116 CASH FLOW, EURM + EBITDA 4 9 8 11 15 11 18 - Net financial items 0 -1 0 -1 -2 0 -2 - Net financial items 0 -1 0 -1 -2 0 -2 - Net financial items 0 -1 0 -1 -2 -2 -2 0 -2 - Net financial items 0 -1 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -1 -1 1 0 0 0 0 0					
Other interest-free debt 1 0 2 2 2 2 2 2 Total liabilities 54 64 79 85 97 107 116 CASH FLOW, EURm + EBITDA 4 9 8 11 15 11 18 - Net financial items 0 -1 0 -1 -2 0 -2 - Net financial items 0 -1 0 -1 -2 0 -2 - Net financial items 0 -1 0 -1 -2 0 -2 - Net financial items 0 -1 0 -1 -2 0 -2 -2 -2 0 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -1 -1 -1 0 0 0 0 0					_
Total liabilities 54 64 79 85 97 107 116 CASH FLOW, EURM + EBITDA 4 9 8 11 15 11 18 - Net financial items 0 -1 0 -1 -2 0 -2 - Net financial items 0 -1 0 -1 -2 0 -2 - Taxes 0 -1 -2 -2 -2 -2 -2 -3 -3 - Increase in Net Working Capital 1 -3 -4 1 3 -3 -2 -2 -2 -2 -2 -2 +7 -3 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td></td> <td></td> <td></td> <td></td> <td>_</td>					_
CASH FLOW, EURm + EBITDA 4 9 8 11 15 11 18 - Net financial items 0 -1 0 -1 -2 0 -2 - Taxes 0 -1 -2 -2 -2 -2 -2 -3 - Increase in Net Working Capital 1 -3 -4 1 3 -3 -2 +/- Other -1 1 0 0 0 0 0 = Cash flow from operations 3 5 1 8 13 6 12 - Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0					
+ EBITDA 4 9 8 11 15 11 18 - Net financial items 0 -1 0 -1 -2 0 -2 - Taxes 0 -1 -2 -2 -2 -2 -2 -3 - Increase in Net Working Capital 1 -3 -4 1 3 -3 -2 +/- Other -1 1 0 0 0 0 0 0 E Cash flow from operations 3 5 1 8 13 6 12 - Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 -2 <					
- Net financial items 0 -1 0 -1 -2 0 -2 - Taxes 0 -1 -2 -2 -2 -2 -2 -3 -3 -2 - Increase in Net Working Capital 1 -3 -4 1 3 -3 -2 -4 1 3 -3 -2 -4 -1 3 -3 -2 -4 1 3 -3 -2 -4 1 3 -3 -2 -4 1 3 -3 -2 -4 1 3 -3 -2 -4 1 3 -3 -2 -2 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td>8 11 15 11 18 21</td> <td>8</td> <td>9</td> <td>4</td> <td></td>	8 11 15 11 18 21	8	9	4	
- Taxes 0 -1 -2 -2 -2 -2 -3 -3 -2 - Increase in Net Working Capital 1 -3 -4 1 3 -3 -2 +/- Other -1 1 0 0 0 0 0 E Cash flow from operations 3 5 1 8 13 6 12 - Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2 -3					
- Increase in Net Working Capital 1 -3 -4 1 3 -3 -2 +/- Other -1 1 0 0 0 0 0 = Cash flow from operations 3 5 1 8 13 6 12 - Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2 -3					
+/- Other -1 1 0 0 0 0 0 = Cash flow from operations 3 5 1 8 13 6 12 - Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2 -3					
= Cash flow from operations 3 5 1 8 13 6 12 - Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2 -3					- ·
- Capex -3 -3 -10 -8 -13 -7 -7 - Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2 -3					,
- Acquisitions 0 0 0 0 0 0 0 + Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2					·
+ Divestments 0 0 0 0 0 0 0 = Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -2					
= Free cash flow 0 1 -9 1 0 -1 5 +/- New issues/buybacks 0 -1 0 0 -1 0 0 - Paid dividend -3 -1 -4 -2 -2 -2 -3					•
+/- New issues/buybacks 0 -1 0 0 -1 0 0 - - Paid dividend -3 -1 -4 -2 -2 -2 -3					
- Paid dividend -3 -1 -4 -2 -2 -2 -3					
±1=11ther 2 7 € ∩	9 3 7 6 0 -5		- i 1	-3 2	+/- Other
Change in cash -1 0 -3 2 5 2 2					
-1 0 -3 2 5 2 2	5	-3	U	=1	Change III Cash

Chemicals/Finland, November 5, 2021 Company update

2017	2018	2019	2020	2021E	2022E	2023E
78	48	78	88	89	89	89
9	28	29	30	34	32	26
87	76	107	118	123	122	116
86	97	104	109	130	147	157
9	8	11	15	11	18	21
6	2	5	9	4	12	15
5	2	4	7	4	10	14
4	0	2	5	2	8	11
29				28		40
	-	-		-		
1.0	0.8	1.0	1.1	1.0	0.8	0.7
						5.5
						7.6
						7.6
						7.4
						9.9
						9.7
						8.2
						2.2
						6.8
						9.5
						15.7
						3.0
0.0	0.0	0.0	0.0	62.4	75.6	10.9
						11,897
						11,897
						0.92
						1.32
						0.78
2.42	2.16	2.21	2.41		2.77	3.39
0.30	0.18	0.18	0.20	0.25	0.30	0.32
85.0	535.4	89.2	44.3	156.0	46.8	34.8
4.6	4.5	2.7	2.7	3.3	4.0	4.3
1.8	-18.3	0.9	0.6	-1.7	5.4	10.3
15.2	1.5	9.2	19.5	6.7	25.0	29.9
14.6	4.5	8.6	14.4	6.2	15.5	17.0
13.5	15.7	16.3	14.9	14.9	14.9	14.9
17.1	20.8	19.2	19.2	19.2	19.2	19.2
21.4	19.2	20.2	22.0	22.0	22.0	22.0
9.3	16.1	14.1	11.2	11.3	11.4	11.5
4.1	9.9	7.3	11.9	5.5	4.5	4.1
4.1	9.9	7.3	11.9	5.5	4.5	4.1
4.1						
		0.3	0.1			
-0.3	-1.5	0.3 2.7	0.1 2.0	0.0	0.4	0.6
-0.3 0.9	-1.5 3.7	2.7	2.0	0.0 3.2	0.4 1.8	0.6 1.2
-0.3	-1.5			0.0	0.4	0.6
	11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897 11,897	86 97 9 8 6 2 5 2 4 0 29 26 1.0 0.8 9.3 9.9 14.2 34.5 14.2 34.5 17.7 84.3 -28.4 -6.6 55.8 -5.5 18.6 119.0 2.7 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11,897 11,897 11,897 11,897 11,897 11,897 0.35 0.03 0.41 0.08 0.12 -0.73 2.42 2.16 0.30 0.18 85.0 535.4 4.6 4.5 1.8 -18.3	86 97 104 9 8 11 6 2 5 5 2 4 4 0 2 29 26 26 10 0.8 1.0 9.3 9.9 10.0 14.2 34.5 21.0 14.2 34.5 21.0 17.7 84.3 12.9 -28.4 -6.6 32.5 55.8 -5.5 110.9 18.6 119.0 32.5 2.7 1.8 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1,897 11,897 11,897 11,897 11,897 11,897 10,00	86 97 104 109 9 8 11 15 6 2 5 9 5 2 4 7 4 0 2 5 29 26 26 29 1.0 0.8 1.0 1.1 9.3 9.9 10.0 7.7 14.2 34.5 21.0 12.5 14.2 34.5 21.0 12.5 17.7 84.3 12.9 8.8 -28.4 -6.6 32.5 52.9 55.8 -5.5 110.9 179.1 18.6 119.0 32.5 16.4 2.7 1.8 3.0 3.1 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11,897	86 97 104 109 130 9 8 11 15 11 6 2 5 9 4 5 2 4 7 4 4 0 2 5 2 29 26 26 29 28 1.0 0.8 1.0 1.1 1.0 9.3 9.9 10.0 7.7 11.5 1.1 1.0 9.3 9.9 10.0 7.7 11.5 1.1.5 1.1.5 1.1.1 1.0 9.3 9.9 10.0 7.7 11.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.5 1.1.1 1.1.0 9.3 9.9 1.1.0 1.1.1 1.1.0 9.3 9.9 9.0 1.1.2 9.0 1.1.2 9.0 1.1.2 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9	86 97 104 109 130 147 9 8 11 15 11 18 6 2 5 9 4 12 5 2 4 7 4 10 4 0 2 5 2 8 29 26 26 29 28 33 1.0 0.8 1.0 1.1 1.0 0.8 9.3 9.9 10.0 7.7 11.5 6.8 14.2 34.5 21.0 12.5 28.1 10.1 14.2 34.5 21.0 12.5 28.1 10.1 17.7 84.3 12.9 8.8 22.0 10.5 28.1 10.1 17.7 28.4 -6.6 32.5 52.9 362.2 16.2 55.8 -5.5 110.9 179.1 -59.9 18.4 18.6 119.0 32.5 16.4 46.9 11.7 2.7 1.8 3.0 3.1 3.2 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0

Chemicals/Finland, November 5, 2021 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Skandinaviska Enskilda Banken AB	1,467,064	11.032	12.3%
Nordea Bank ABP	942,402	7.087	7.9%
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	6.016	6.7%
OP-Finland Small Firms Fund	590,119	4.438	5.0%
Danske Invest Finnish Equity Fund	475,000	3.572	4.0%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	3.158	3.5%
Phoebus Fund	350,000	2.632	2.9%
Säästöpankki Pienyhtiöt	288,710	2.171	2.4%
Ilmarinen Mutual Pension Insurance	242,733	1.825	2.0%
Veritas Pension Insurance Company Ltd.	226,163	1.701	1.9%
Ten largest	5,802,191	43.632	49%
Residual	6,094,652	45.832	51%
Total	11,896,843	89.464	100%

EARNINGS CALENDAR	
February 15, 2022	FY 2021 Results
April 29, 2022	Q1 report
July 20, 2022	Q2 report
November 03, 2022	Q3 report

OTHER EVENTS

COMPANY MISCELLANEOUS

CEO: Riku Kytömäki Mäkituvantie 5 01510 Vantaa
CFO: Mikko Kettunen Tel: +358 20 7541 200
IR: Noora Koikkalainen

Chemicals/Finland, November 5, 2021 Company update

DEFINITIONS

P/E	EPS
Price per share Earnings per share	Profit before extraord. items and taxes— income taxes + minority interest Number of shares
P/BV	DPS
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Enterprise value Sales	Free cash flow Market cap
EV/EBITDA	Operative CAPEX/sales
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares
Total assets	Gearing
Balance sheet total	<u>Net debt</u> Equity
Div yield, %	Debt/Equity, %
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, November 5, 2021 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [5.11.2021, 9:15]. This report has been published on [5.11.2021, 9:30].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, November 5, 2021 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, November 5, 2021 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sale	s	Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 352 6175
Evli Investment Solutions			
Johannes Asuia	+358 9 4766 9205		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001